InvestorsHub Logo
Followers 40
Posts 2492
Boards Moderated 0
Alias Born 04/07/2012

Re: salgovernale69 post# 704

Wednesday, 06/24/2015 7:51:58 AM

Wednesday, June 24, 2015 7:51:58 AM

Post# of 8344
"Our findings that TNX-201 selectively modulates a receptor in the central nervous system that appears to regulate pain perception and responses, together with positive data in two rodent models representative of migraine, support the development of TNX-201 as a therapeutic for headache and potentially other pain indications and one that may be differentiated from currently-approved products," said Bruce Daugherty, Ph.D., Tonix's chief scientific officer. "We look forward to reporting the results of our Phase 2 POC study in episodic tension-type headache in the fourth quarter of this year."

I agree, IMO, this still has a good ways to run!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TNXP News